AcroMeta Group enters cell therapy logistics market with Macro HRD partnership
Singapore-based AcroMeta Group Limited has signed a strategic partnership to acquire a stake in ambient temperature cellular logistics technology, targeting the rapidly growing Southeast Asian cell and gene therapy market.
AcroMeta to Enter Ambient Temperature Cellular Logistics Through Strategic Partnership with Macro HRD SG Pte. Ltd.
AcroMeta Group Limited has entered into a non-binding term sheet with Macro HRD SG Pte. Ltd. to establish a strategic partnership in the emerging field of ambient temperature cellular logistics. The agreement provides AcroMeta with an opportunity to acquire a strategic stake in Macro-ATCLS Pte. Ltd., the entity commercializing the Ambient Temperature Cellular Logistics technology.
The Singapore-listed company, which operates through its Maintenance segment providing installation and maintenance services for controlled environments and its Co-working Laboratory Space segment managing research and technology facilities, is expanding beyond its core operations. AcroMeta was formerly known as ACROMEC Limited before changing its name in February 2022.
Lawrence Toh, Executive Director of AcroMeta Group Limited, said the partnership represents a natural extension of the company's growth strategy.
This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead,Toh stated during the signing ceremony with Kawinyarat Mardpiratchata, CFO and Managing Partner of Macro-HRD Pte. Ltd.
Technology addressing cold chain challenges
The Ambient Temperature Cell Logistics technology is designed to transform the transportation of living cells and temperature-sensitive biological materials by eliminating reliance on conventional refrigerated and cryogenic cold chains. Current cell and gene therapy logistics require ultra-low temperature storage, often below -150°C, using liquid nitrogen dewars and dry ice containers with strict chain-of-identity protocols to prevent fatal mix-ups in autologous therapies.
These cryogenic systems face significant operational challenges. Cryopreservation can cause cell dysfunction and reduced cell viability from freezing injury, while the high costs of cryogenic infrastructure, supply chain disruptions, and complex regulatory requirements for maintaining product integrity during transport create substantial barriers. Industry surveys indicate that approximately 50% of cell and gene therapy experts identify storage and warehousing of cold chain materials, logistics to manufacturing facilities, and end-product manufacturing as primary concerns in the supply chain.
The ATCLS platform uses proprietary ambient-temperature preservation and reactivation technologies, supported by its Gradient Equilibrium Decision Modeling platform for real-time governance, chain-of-identity and process control. The system enables dormant living cells to be transported at ambient temperature and reactivated at the point of use.
Market opportunity and projections
The technology addresses markets including stem cells, CAR-T and immune-cell therapy, gene therapy, regenerative medicine, and organ and tissue transplantation. According to project materials, underlying markets range from US$5.2 billion for immune-cell therapy to US$47 billion for organ transplantation. The global CAR T-cell therapy market, valued between US$5.2 billion and US$7.84 billion in 2025, is projected to grow at compound annual growth rates ranging from 13.5% to 29.3% through the 2030s.
The cell and gene therapy third-party logistics market is experiencing rapid growth, with industry projections showing the sector expanding from between US$1.81 billion and US$10.75 billion in 2024-2025 to between US$16.95 billion and US$30.67 billion by 2034-2035, representing growth rates ranging from 10.3% to 25.1% annually. Market trends indicate that newer gene therapies and advanced biologics are becoming more stable, requiring less extreme temperature control compared to initial cryogenic requirements.
Based on defined ambient-addressable segments, ATCLS estimates a Serviceable Addressable Market of approximately US$14.5 billion by 2032. The cell and gene therapy supply chain involves multiple stakeholders including manufacturing facilities, third-party logistics companies, and medical centers, with challenges arising from product characteristics, regulatory requirements, and infrastructure gaps that affect coordination during product handover events.
Exclusive licensing arrangement
Under the proposed agreement, AcroMeta will have an option to acquire an exclusive licence to deploy the ATCLS technology across agreed territories in Southeast Asia, including the right to appoint sub-licensees. The company is listed on the Catalist board of the Singapore Exchange, a sponsor-supervised listing platform with no minimum quantitative criteria for operating track record, profit, or share capital requirements.
The exclusive licensing structure is intended to provide AcroMeta with rights to develop and commercialize the ATCLS business within Southeast Asia, together with a first right to acquire additional territories. The Board stated it remains focused on disciplined capital allocation as the Group evaluates strategic opportunities to support long-term value creation for shareholders.
Macro HRD is a Singapore-based biotechnology and therapeutics company established in 2024, focused on developing precision-medicine solutions for high-burden infectious diseases. The company integrates advanced biology, therapeutic platform technologies and AI/ML-enabled decision systems to accelerate drug discovery and translational development.